00:00/00:00
您的浏览器不支持 audio 标签。
Listen to this article
1x
China will allow more originator drugs to re-enter its national bulk-procurement program after missing the initial bidding round, expanding a mechanism intended to limit cutthroat price competition and preserve access to brand-name medicines in hospitals.
